The world of hearing technology has always moved forward incrementally — a slightly smaller device, a marginally better algorithm, an improved wireless connection. But every few years, something genuinely different emerges. Two technologies have drawn serious clinical attention recently: the Earlens light-driven contact hearing aid and the Lenire bimodal neuromodulation device for tinnitus. Neither is a household name. Many patients have never heard of either. But the peer-reviewed evidence supporting both has grown substantially, and understanding what they do — and who they’re designed for — matters.
What Is Earlens?
Most hearing aids work the same way: a microphone captures sound, a processor amplifies it, and a miniature speaker delivers that amplified sound into the ear canal. This works well for millions of people — but conventional speakers have a hard ceiling. Getting clean amplification above 6,000 Hz is difficult in a miniaturized device, and frequencies above 8,000 Hz are nearly impossible to amplify without distortion or acoustic feedback. For patients who depend on those high frequencies for consonant clarity — particularly in background noise — this is a meaningful limitation.
Earlens solves this by eliminating the speaker entirely. Instead of projecting sound through air, Earlens uses modulated light to drive a miniaturized tympanic contact transducer — a small lens resting directly on the eardrum — causing the eardrum to vibrate in a way that closely mimics natural hearing. The bandwidth difference is real. In a peer-reviewed study published in Ear and Hearing (Ricketts & Picou, 2019), Earlens users demonstrated functional gain extending to 10,000 Hz, with word recognition improvements averaging 35 percentage points in aided conditions. A follow-up study (Gantz et al., 2021) confirmed that Earlens provides adequate output for patients with hearing loss up to 60 dBHL at 8 kHz in approximately 86% of cases — a benchmark conventional hearing aids rarely reach.
Earlens is not for everyone. The transducer requires professional placement, and approximately 11% of participants in the FDA pivotal safety study discontinued use, primarily due to autophony or a sensation of fullness. Candidacy requires adequate residual hearing in the low and mid frequencies. But for patients frustrated with poor clarity in noise despite wearing conventional aids — particularly those with sharply sloping high-frequency loss — the technology represents a meaningful departure from existing options.
What Is Lenire?
Tinnitus affects an estimated 15% of the global population and remains one of the most underserved conditions in medicine. Existing treatments — sound therapy, cognitive behavioral therapy, hearing aids with masking features — offer meaningful relief for many patients, but they don’t address the maladaptive neural circuits that generate the perception of sound where none exists. Lenire was designed with that gap in mind.
Lenire combines specific sound stimulation delivered through headphones with simultaneous gentle electrical stimulation of the tongue — a technique called bimodal neuromodulation. The premise is that pairing auditory input with somatosensory input from the tongue can help recalibrate the abnormal neural activity responsible for tinnitus. The treatment protocol involves 10 minutes of daily use for 12 weeks.
The clinical evidence is now compelling. In the TENT-A3 trial — a multi-site controlled pivotal study published in Nature Communications in 2024 (Conlon et al.) — participants with moderate or more severe tinnitus who received bimodal treatment achieved a clinically significant response rate of 58.6%, compared to 43.2% with sound-only stimulation. Clinically significant improvement was defined as a 7-point or greater reduction on the Tinnitus Handicap Inventory, a validated outcome measure. In a 2025 real-world retrospective study published in Communications Medicine (Conlon et al.) examining 212 patients across clinical practices, 91.5% of patients were classified as responders, with a mean improvement of 27.8 points. No serious device-related adverse events were reported in either study.
The FDA cleared Lenire in 2023, following the TENT-A3 data. That regulatory clearance is significant — it reflects not just academic evidence but the scrutiny of formal review.
Who Are These Devices For?
Earlens is best considered for patients with sensorineural hearing loss who have already tried conventional aids and remain dissatisfied with clarity in noise or with speech understanding — particularly those with steeply sloping audiograms. Lenire is most appropriate for patients with moderate to severe tinnitus who haven’t found adequate relief through standard management. Both are prescription devices requiring evaluation and fitting by a qualified audiologist. Neither is currently covered by most insurance plans.
Neither Earlens nor Lenire is currently offered at Pinnacle Audiology. But both represent something important: proof that hearing care is expanding beyond its conventional boundaries, and that the standard toolkit — while excellent for most patients — is no longer the ceiling of what’s possible.
References
- Ricketts, T.A. & Picou, E.M. (2019). Achieved gain and subjective outcomes for a wide-bandwidth contact hearing aid fitted using CAM2. Ear and Hearing. PMC6453763.
- Gantz, B.J., et al. (2021). Detection, speech recognition, loudness, and preference outcomes with a direct drive hearing aid: effects of bandwidth. PMC8060758.
- Conlon, B., et al. (2024). Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial. Nature Communications. PMC11333749.
- Conlon, B., et al. (2025). Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting. Communications Medicine. PMC12037789.